{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-108655","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.349474+00:00","generated_at":"2026-05-16T21:49:31.518237+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"GX-03 named one of five novel mechanisms in atopic dermatitis by Patient Care Online","bullets":["GX-03 technology recognized by Patient Care Online alongside candidates from Amgen, Sanofi, Leo Pharma, Apogee, and Nektar.","CEO states GX-03 is first topical IL-36/IL-31 inhibitor; topline data for severe eczema expected early 2026.","CEO Bradley Burnam interviewed former CDC Director Dr. Robert Redfield on podcast about restoring trust in science."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-108655","json":"https://secwatch.observer/filing/0001213900-25-108655.json","markdown":"https://secwatch.observer/filing/0001213900-25-108655.md","text":"https://secwatch.observer/filing/0001213900-25-108655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390025108655/0001213900-25-108655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390025108655/ea0265235-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:49:31.518237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}